Scholarlink

<p>This letter explores recent innovations and challenges in beta cell replacement therapies for diabetes, emphasizing the gap between promising bioengineering techniques and clinical applicability. While advancements like stem cell-derived beta cells and bioartificial pancreas models show potential, concerns remain regarding immune rejection, maturation of beta cells, and long-term safety. Current strategies lack focus on type 2 diabetes, which constitutes the majority of cases. Moreover, issues such as vascularization, fibrosis, and ethical implications require further exploration. Bridging scientific breakthroughs with real-world application necessitates rigorous preclinical validation and scalability strategies to ensure safe, effective, and inclusive treatment for the global diabetic population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bridging innovation and clinical impact: advances and challenges in beta cell replacement therapies

  • 期刊论文

  • 发表日期：

    2025年10月21日

查看全文
  • Muhammad Naveed,
  • Uzair Ahmad Mahar,
  • Muhammad Mustafa,
  • Wajiha Asim

摘要

This letter explores recent innovations and challenges in beta cell replacement therapies for diabetes, emphasizing the gap between promising bioengineering techniques and clinical applicability. While advancements like stem cell-derived beta cells and bioartificial pancreas models show potential, concerns remain regarding immune rejection, maturation of beta cells, and long-term safety. Current strategies lack focus on type 2 diabetes, which constitutes the majority of cases. Moreover, issues such as vascularization, fibrosis, and ethical implications require further exploration. Bridging scientific breakthroughs with real-world application necessitates rigorous preclinical validation and scalability strategies to ensure safe, effective, and inclusive treatment for the global diabetic population.